Seneca Biopharma Inc fka SNCA

[BesaoT35]

Current shares outstanding is 20 million. After the reverse split there should be only 1 million shares outstanding at $8.00 + per share. The market cap being unchanged at around $8 million.

If NSI-189 has any potential we should be worth $8 million. The neural stem cells should also have some value for the shareholders.

NVIV is doing spinal scaffolds to grow axons in the human spine after trauma. They are in their second clinical trial with 8 research hospitals participating. Few patients are enrolling however. Combining the scaffold with stem cells and neural growth factors could just be the ticket for greater success. I would think this would be obvious.

I wonder whether NVIV and CUR have talked to each other.